Neural Stem Cell Cargo Delivery Across the Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting invasive tumors due to the limitations of the blood-brain barrier and toxicity to normal tissues, necessitating a more targeted and less toxic delivery method.
Innovation Solution
Neural stem cells (NSCs) engineered to express anti-cancer agents and encapsulate exogenous nucleic acids, such as Toll-like receptor-binding sequences, are administered to target and activate immune responses in the tumor microenvironment, minimizing toxicity to normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are administered systemically, then therapeutic agents can reach tumor sites, but toxicity to normal tissues occurs and the blood-brain barrier limits efficacy
Solution Approach 1:
Neural stem cells serve as intermediary delivery vehicles that carry anti-cancer agents to tumor sites. The NSCs cross the blood-brain barrier and deliver therapeutic payloads directly to brain tumors, eliminating the need for systemic administration and reducing toxicity to normal tissues. The NSCs act as a targeted transport system between the bloodstream and tumor cells.
Solution Approach 2:
The patent creates locally concentrated therapeutic action by delivering anti-cancer agents directly to tumor sites through NSC-mediated transport. The therapeutic effect is localized to the tumor microenvironment rather than being distributed systemically, achieving high efficacy at the target site while minimizing exposure and toxicity to healthy tissues throughout the body.
2Reliability
If the blood-brain barrier is crossed by therapeutic agents, then brain tumors can be treated, but delivery efficiency is reduced by the barrier
Solution Approach 1:
Neural stem cells serve as specialized intermediary carriers that naturally cross the blood-brain barrier through their inherent biological properties. Rather than attempting to force therapeutic agents through the barrier, the patent uses NSCs as living vehicles that naturally navigate the barrier and deliver their cargo directly to brain tumor sites, dramatically improving delivery efficiency.
Solution Approach 2:
The patent alters the delivery mechanism by changing from direct chemical agent administration to biological carrier-mediated transport. This parameter change exploits the unique biological properties of neural stem cells, including their ability to home to tumor sites and cross physiological barriers, thereby achieving efficient brain tumor delivery that overcomes the limitations of conventional approaches.
3Reliability
If neural stem cells are engineered to express anti-cancer agents, then targeted delivery is achieved, but device complexity increases
Solution Approach 1:
The patent employs universal neural stem cell platforms that can deliver multiple types of anti-cancer agents including prodrug-activating enzymes, apoptosis-inducing agents, antibodies, and oncolytic viruses. This multi-functional approach allows a single NSC delivery system to address various tumor types and therapeutic needs without requiring separate engineered cell lines for each agent, thereby managing complexity while maintaining targeted delivery accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NSCs provide targeted delivery of therapeutic agents to brain tumors, enhancing anti-cancer efficacy by activating immune responses and reducing toxicity to normal tissues.
Implementation Method 1
NSCs internalize the oligonucleotides and continuously release EVs containing the oligonucleotides for 2-3 days
Implementation Method 2
NSCs internalize the oligonucleotides and continuously release EVs containing the oligonucleotides for 2-3 days
Implementation Method 3
The neural stem cells were treated with CpG oligodeoxynucleotides (ODNs), which are known to bind to and activate Toll-like receptor 9 (TLR9)
Data Source
AI summary
The disclosure provides, inter alia, neural stem cells comprising exogenous nucleotides, vesicles comprising exogenous nucleotides, and methods for treating diseases and disorders, such as cancer, neurodegenerative diseases, inflammatory diseases, and viral diseases, using the neural stem cells, vesicles, and pharmaceutical compositions comprising them.